Research Paper Volume 14, Issue 13 pp 5571—5589
A novel prognostic signature of metastasis-associated genes and personalized therapeutic strategy for lung adenocarcinoma patients
Figure 12. The relationship of risk signature with chemotherapy response. Difference of IC50 value between high- and low-risk groups for common chemotherapeutics drugs including Bleomycin, Cisplatin, Docetaxel, Gefitinib, Gemcitabine, Paclitaxel, Vinblastine, and Vinorelbine.